Mirum Pharmaceuticals (MIRM) PT Raised to $189 at Raymond James
Bullish analyst view, tempered by the shares’ move since the signal and the uncertainty inherent in price targets.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst view, tempered by the shares’ move since the signal and the uncertainty inherent in price targets.
What happened, with direct paths to the underlying reporting
Raymond James raised its price target to $189, versus the posted price of $87.03. The target implies substantial upside, though it is an analyst opinion and the shares have already risen 11.42% since the signal.
Target: $189
Posted price: $87.03
Analyst firm: Raymond James
Analyst: Steven Seedhouse
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.